Literature DB >> 11996324

Biotransformation of the ipecac alkaloids cephaeline and emetine from ipecac syrup in rats.

Takayuki Asano1, Junko Watanabe, Chiharu Sadakane, Kazuhisa Ishihara, Kazuhiro Hirakura, Yoko Wakui, Toshihiko Yanagisawa, Masayuki Kimura, Hideo Kamei, Takemi Yoshida, Yuichi Fujii, Mamoru Yamashita.   

Abstract

The metabolism of cephaeline and emetine, which are the primary active components of ipecac syrup, were investigated in rats. Cephaeline-6'-O-glucuronide was found to be a biliary metabolite of cephaeline. Cephaeline (6'-O-demethylemetine) and 9-O-demethylemetine were observed to be enzyme-hydrolyzed biliary metabolites of emetine. Cephaeline was conjugated to glucuronide, while emetine was demethylated to cephaeline and 9-0-demethylemetine, and may be conjugated to glucuronides afterwards. Urine, feces and bile were collected from rats within 48 hours following the administration of ipecac syrup containing tritium (3H)--labeled cephaeline or emetine. Metabolites were separated and quantified by thin layer chromatography (TLC) or high-performance liquid chromatography (HPLC). Biliary and urinary excretion rates of 3H-cephaeline were 57.5% and 16.5% of the dose, respectively. Cephaeline-6'-O-glucuronide was comprised 79.5% of biliary radioactivity and 84.3% of urinary radioactivity. Unchanged cephaeline was detected in 42.4% of the dose in feces. Biliary excretion rate of 3H-emetine was 6.9% of the dose. Emetine, cephaeline and 9-0-demethylemetine comprised 5.8%, 43.2% and 13.6% in hydrolyzed bile, respectively. There were no emetine-derived metabolites in urine or feces. The occurrence of unchanged emetine was 6.8% and 19.7% of the dose in urine and feces, respectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996324     DOI: 10.1007/BF03190402

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  10 in total

1.  [Determination of cephaeline in Radix Ipecacuanhae].

Authors:  M Sobiczewska; B Borkowski
Journal:  Acta Pol Pharm       Date:  1970       Impact factor: 0.330

2.  Death resulting from ipecac syrup poisoning.

Authors:  A G Adler; P Walinsky; R A Krall; S Y Cho
Journal:  JAMA       Date:  1980-05-16       Impact factor: 56.272

3.  Toxic alkaloids and their interaction with microsomal cytochrome P-450 in vitro.

Authors:  A Peeples; R R Dalvi
Journal:  J Appl Toxicol       Date:  1982-12       Impact factor: 3.446

4.  Absorption, distribution and excretion of 3H-labeled cephaeline- and emetine-spiked ipecac syrup in rats.

Authors:  Takayuki Asano; Kazuhisa Ishihara; Yoko Wakui; Toshihiko Yanagisawa; Masayuki Kimura; Hideo Kamei; Takemi Yoshida; Yukio Kuroiwa; Yuichi Fujii; Mamoru Yamashita; Takanori Kuramochi; Hiroki Tomisawa; Mitsuru Tateishi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.441

5.  Toxicology of ipecac: a review.

Authors:  B R Manno; J E Manno
Journal:  Clin Toxicol       Date:  1977       Impact factor: 4.467

6.  Emetine myopathy: two case reports with pathobiochemical analysis.

Authors:  H Sugie; R Russin; M A Verity
Journal:  Muscle Nerve       Date:  1984-01       Impact factor: 3.217

7.  Ultrastructural pathology in emetine-induced myopathy.

Authors:  L Halbig; L Gutmann; H H Goebel; J F Brick; S Schochet
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

8.  Ipecac myopathy and cardiomyopathy.

Authors:  L P Dresser; E W Massey; E E Johnson; E Bossen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

9.  Effects of pharmacological interventions on emetine cardiotoxicity in isolated perfused rat hearts.

Authors:  S J Pan; A B Combs
Journal:  Toxicology       Date:  1995-03-31       Impact factor: 4.221

10.  A model system for measuring comparative toxicities of cardiotoxic drugs with cultured rat heart myocytes, endothelial cells and fibroblasts. I. Emetine, chloroquine and metronidazole.

Authors:  D G Wenzel; G N Cosma
Journal:  Toxicology       Date:  1984-11       Impact factor: 4.221

  10 in total
  2 in total

1.  Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences.

Authors:  Aoli Wang; Yong Sun; Qingwang Liu; Hong Wu; Juan Liu; Jun He; Junling Yu; Qing Qing Chen; Yinglu Ge; Zhuhui Zhang; Chen Hu; Cheng Chen; Ziping Qi; Fengming Zou; Feiyang Liu; Jie Hu; Ming Zhao; Tao Huang; Beilei Wang; Li Wang; Wei Wang; Wenchao Wang; Tao Ren; Jing Liu; Yehuan Sun; Song Fan; Qibing Wu; Chaozhao Liang; Liangdan Sun; Bin Su; Wei Wei; Qingsong Liu
Journal:  Mol Biomed       Date:  2020-11-30

2.  Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences.

Authors:  Aoli Wang; Yong Sun; Qingwang Liu; Hong Wu; Juan Liu; Jun He; Junling Yu; Qing Qing Chen; Yinglu Ge; Zhuhui Zhang; Chen Hu; Cheng Chen; Ziping Qi; Fengming Zou; Feiyang Liu; Jie Hu; Ming Zhao; Tao Huang; Beilei Wang; Li Wang; Wei Wang; Wenchao Wang; Tao Ren; Jing Liu; Yehuan Sun; Song Fan; Qibing Wu; Chaozhao Liang; Liangdan Sun; Bin Su; Wei Wei; Qingsong Liu
Journal:  Mol Biomed       Date:  2020-11-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.